Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis

NCT02228213 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

93

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary Progressive Multiple Sclerosis

Interventions

BIOLOGICAL: MIS416
DRUG: Saline

Sponsor

Innate Immunotherapeutics

Collaborators

[object Object]